Feb 24, 2020 04:06 PM IST
Nifty marked its biggest fall since February 1, ending with a deep cut of 251 points, or 2.08 percent, at 11,829.40.
- Feb 24, 2020 02:06 PM IST
The company reported a 14.5 percent growth in its December quarter profit at Rs 880 crore versus Rs 769.1 crore in October-December of 2018.
- Feb 24, 2020 11:37 AM IST
Volumes grew about 7 percent YoY while cement realisation climbed nearly 3 percent YoY, lead to top-line growth of 10 percent.
- Feb 24, 2020 10:49 AM IST
RCom's secured debt is estimated to be around Rs 33,000 crore. Lenders submitted claims of around Rs 49,000 crore in August.
- Feb 24, 2020 10:19 AM IST
Both the stocks came on investors' radar after they entered into a confidentiality and exclusivity arrangement to explore a long-term strategic partnership.
- Feb 24, 2020 09:55 AM IST
Shares of the company got traction after the Competition Commission of India gave approval for the GMR group's proposed 49 percent stake sale in its airport business to France's Groupe ADP.
- Feb 20, 2020 11:45 AM IST
Macquarie sees the stock in a positive light. It has an outperform view on the stock with a 12-month target price of Rs 1,850.
- Feb 18, 2020 10:29 AM IST
According to a release filed with the exchanges, the company would pay another Rs 1,000 crore to the DoT before the end of the week.
- Feb 17, 2020 09:11 PM IST
Key support level for Nifty is placed at 12002, followed by 11958.2. If the index continues moving up, key resistance levels to watch out for are 12124.6 and 12203.4.
- Feb 16, 2020 11:13 AM IST
Last week, the Sensex climbed 115.89 points or 0.28%.
- Feb 14, 2020 02:40 PM IST
The move effective from February 13 has been taken as these brokers failed to comply with the NSE guidelines, they added.
- Feb 14, 2020 12:23 PM IST
The Kishore Biyani-led company reported a 16.72 percent decline in consolidated net profit at Rs 164.56 crore for the third quarter ended December.
- Feb 14, 2020 10:51 AM IST
The company had posted consolidated loss of Rs 21.16 crore in the year-ago period, Gammon Infrastructure Projects said in a filing to BSE.
- Feb 13, 2020 02:02 PM IST
The bank said that it will release its December quarter earnings on or before March 14.
- Feb 13, 2020 12:29 PM IST
"Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use...1000 mg," the drug firm said in a regulatory filing.
- Feb 13, 2020 12:27 PM IST
"US Food & Drug Administration (USFDA) has tentatively approved its Abbreviated New Drug Application for Guaifenesin extended-release tablets, 600 mg and 1200 mg (OTC)," the company said in a filing to the BSE.
- Feb 11, 2020 05:50 PM IST
Total income declined to Rs 148.66 crore in the October-December period of the ongoing fiscal from Rs 177.11 crore in the same quarter previous financial year.
- Feb 11, 2020 03:37 PM IST
The US Food and Drug Administration (USFDA) has tentatively approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals Inc for Colchicine capsules in the strength of 0.6 mg, Granules India said in a filing to the BSE.
- Feb 11, 2020 01:40 PM IST
The earnings of the company failed to impress the market as brokerages came out with mixed views on the stock.
- Feb 11, 2020 12:31 PM IST
The company declared an interim dividend of Rs 10 per share (100 percent) for the financial year 2019-20.
- Feb 11, 2020 11:21 AM IST
Credit Suisse is of the view that M&M's tractor segment performance was in-line both on revenue and margin.
- Feb 11, 2020 10:50 AM IST
Morgan Stanley has an equal-weight call on the stock with a target price of Rs 401. Nomura has maintained a neutral rating on the stock with a target raised to Rs 475.
- Feb 10, 2020 04:01 PM IST
The company has allotted rated, listed, secured, redeemable, non-convertible debentures on private placement basis for an issue size of Rs 500 crore, STFC said in a regulatory filing.
- Feb 10, 2020 03:56 PM IST
The net profit at Rs 1,250.65 crore, or Rs 2.77 a share, in October-December, was 25.6 percent lower than Rs 1,681.23 crore, or Rs 3.73 per share, profit earned in the same period a year ago, the company said in regulatory filings.
- Feb 10, 2020 03:40 PM IST
The company's topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit, Cadila Healthcare said in a filing to the BSE.